B. Riley Financial Reaffirms Buy Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reiterated by B. Riley Financial in a research note issued to investors on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock, down from their prior price objective of $28.00. B. Riley Financial’s price target points to a potential upside of 78.28% from the stock’s previous close.

A number of other research firms also recently weighed in on OPRX. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Zacks Research downgraded OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stifel Nicolaus decreased their target price on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday. Stephens lowered their target price on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Citizens Jmp increased their price target on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

OptimizeRx Stock Down 18.1%

OptimizeRx stock traded down $1.36 during mid-day trading on Friday, reaching $6.17. The company’s stock had a trading volume of 949,598 shares, compared to its average volume of 379,532. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The business’s 50 day simple moving average is $10.63 and its 200 day simple moving average is $14.80. The company has a market capitalization of $115.01 million, a price-to-earnings ratio of 19.67 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. As a group, research analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx declared that its board has authorized a share repurchase program on Thursday, March 5th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its position in shares of OptimizeRx by 600.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after buying an additional 1,818 shares in the last quarter. Quantbot Technologies LP bought a new position in OptimizeRx during the 2nd quarter worth $44,000. BNP Paribas Financial Markets increased its stake in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the period. State of Alaska Department of Revenue acquired a new position in OptimizeRx in the 4th quarter valued at $62,000. Finally, USA Financial Formulas bought a new stake in shares of OptimizeRx during the 3rd quarter valued at $131,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx News Summary

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results topped estimates — OPRX reported $0.51 EPS and $32.24M in revenue, beating consensus and highlighting continued revenue growth. This is the fundamental positive underpinning the shares. GlobeNewswire: Press Release
• Positive Sentiment: Board authorized a $10.0M share repurchase (up to ~6.8% of shares), a signal management views the stock as undervalued and a potential support for the share price. RTT News: Buyback
• Neutral Sentiment: Company-hosted earnings call and multiple transcripts are available for investors to assess management commentary and execution plans; useful for judging sustainability of growth and margin outlook. Yahoo Finance: Earnings Highlights
• Neutral Sentiment: Trading experienced repeated LULD pauses (multiple intraday halts) — this indicates elevated volatility and may have contributed to larger intraday moves and volume. (Market notices reported multiple LULD pauses.)
• Negative Sentiment: FY‑2026 revenue guidance of $109M–$114M came in materially below the consensus (~$122M), creating the primary negative catalyst pushing the stock lower as investors reprice forward growth expectations. Seeking Alpha: Guidance
• Negative Sentiment: Stephens cut its price target from $17 to $10 and moved to an “equal weight” rating, sending a clear signal to investors and likely amplifying selling pressure from analysts/quant strategies. Benzinga: Analyst Note

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.